| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_97c064d391008e6e6ea1f603a7dc781c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b9cc2d8f832624f015bd24bec47ef697
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c9040223f4527c0dedc4fe32a573bd65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9e584d8bb09004360df6224730b50869 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-8132
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate |
2008-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2012-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eea39b5c584b75b45b315e65c23c5c88
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae327c205759d4b8e5767960f0ecd1e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be10e7bb955687838ea436bd6bea3049 |
| publicationDate |
2012-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8211858-B2 |
| titleOfInvention |
Modified plasminogen activator inhibitor type-1 molecule and methods based thereon |
| abstract |
The present invention relates to a modified plasminogen activator inhibitor type-1 (PAI-1) molecule that displays an increased in vivo half-life of the active form of PAI-1, but is deficient in one or more functional activities as compared to the wild-type PAI-1 protein. The modified PAI-1 molecule that displays an increased half-life further displays at least one of the following functional characteristics: (i) decreased binding activity to at least one of the following molecules: urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA) and vitronectin (Vn); and (ii) decreased specific activity against at least one of the following molecules: uPA, tPA and Vn. The invention further relates to pharmaceutical compositions comprising modified PAI-1 molecules and methods of using these pharmaceutical compositions for treatment. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10030048-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11773135-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11174286-B2 |
| priorityDate |
2007-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |